277 related articles for article (PubMed ID: 20826724)
21. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease.
Lucas KG; Salzman D; Garcia A; Sun Q
Cancer; 2004 May; 100(9):1892-901. PubMed ID: 15112270
[TBL] [Abstract][Full Text] [Related]
22. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
[TBL] [Abstract][Full Text] [Related]
23. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation.
Leen AM; Christin A; Myers GD; Liu H; Cruz CR; Hanley PJ; Kennedy-Nasser AA; Leung KS; Gee AP; Krance RA; Brenner MK; Heslop HE; Rooney CM; Bollard CM
Blood; 2009 Nov; 114(19):4283-92. PubMed ID: 19700662
[TBL] [Abstract][Full Text] [Related]
24. Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells.
Ricciardelli I; Blundell MP; Brewin J; Thrasher A; Pule M; Amrolia PJ
Blood; 2014 Oct; 124(16):2514-22. PubMed ID: 25185261
[TBL] [Abstract][Full Text] [Related]
25. Successful management of EBV-PTLD in allogeneic bone marrow transplant recipient by virological-immunological monitoring of EBV infection, prompt diagnosis and early treatment.
Chiereghin A; Bertuzzi C; Piccirilli G; Gabrielli L; Squarzoni D; Turello G; Ferioli M; Sessa M; Bonifazi F; Zanoni L; Sabattini E; Lazzarotto T
Transpl Immunol; 2016 Feb; 34():60-4. PubMed ID: 26687013
[TBL] [Abstract][Full Text] [Related]
26. Virus-specific T-cells from third party or transplant donors for treatment of EBV lymphoproliferative diseases arising post hematopoietic cell or solid organ transplantation.
O'Reilly RJ; Prockop S; Oved JH
Front Immunol; 2023; 14():1290059. PubMed ID: 38274824
[TBL] [Abstract][Full Text] [Related]
27. The efficacy and safety of Epstein-Barr virus-specific antigen peptide-activated cytotoxic T-cells treatment for refractory or recurrent angioimmunoblastic T-cell lymphoma: A prospective clinical observational study.
Bingjie W; Lihong W; Yongjin S; Huihui L; Jinping O; Xi'nan C
Hematol Oncol; 2020 Aug; 38(3):272-276. PubMed ID: 32083758
[TBL] [Abstract][Full Text] [Related]
28. Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk.
Van Besien K; Bachier-Rodriguez L; Satlin M; Brown MA; Gergis U; Guarneri D; Hsu J; Phillips AA; Mayer SA; Singh AD; Soave R; Rossi A; Small CB; Walsh TJ; Rennert H; Shore TB
Leuk Lymphoma; 2019 Jul; 60(7):1693-1696. PubMed ID: 30741059
[TBL] [Abstract][Full Text] [Related]
29. T-cell lymphoma with a granulomatous lesion of the lungs after autologous hematopoietic stem cell transplantation for Epstein-Barr virus-positive diffuse large B-cell lymphoma: a unique rare case of metachronous B-cell and T-cell lymphoma.
Kajimoto Y; Terasaki Y; Terasaki M; Kunugi S; Okabe Y; Wakita S; Inokuchi K; Shimizu A
Diagn Pathol; 2020 Oct; 15(1):125. PubMed ID: 33036636
[TBL] [Abstract][Full Text] [Related]
30. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.
Heslop HE; Slobod KS; Pule MA; Hale GA; Rousseau A; Smith CA; Bollard CM; Liu H; Wu MF; Rochester RJ; Amrolia PJ; Hurwitz JL; Brenner MK; Rooney CM
Blood; 2010 Feb; 115(5):925-35. PubMed ID: 19880495
[TBL] [Abstract][Full Text] [Related]
31. A population-based study of 135 lymphomas after solid organ transplantation: The role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival.
Kinch A; Baecklund E; Backlin C; Ekman T; Molin D; Tufveson G; Fernberg P; Sundström C; Pauksens K; Enblad G
Acta Oncol; 2014 May; 53(5):669-79. PubMed ID: 24164103
[TBL] [Abstract][Full Text] [Related]
32. Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation.
Blaes AH; Cao Q; Wagner JE; Young JA; Weisdorf DJ; Brunstein CG
Biol Blood Marrow Transplant; 2010 Feb; 16(2):287-91. PubMed ID: 19835968
[TBL] [Abstract][Full Text] [Related]
33. Immune-cell treatment of Epstein--Barr-virus-associated lymphoproliferative disorders.
Swinnen LJ
Best Pract Res Clin Haematol; 2006; 19(4):839-47. PubMed ID: 16997187
[TBL] [Abstract][Full Text] [Related]
34. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
[TBL] [Abstract][Full Text] [Related]
35. Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of epstein-barr virus-associated diseases.
Wilkie GM; Taylor C; Jones MM; Burns DM; Turner M; Kilpatrick D; Amlot PL; Crawford DH; Haque T
J Immunother; 2004; 27(4):309-16. PubMed ID: 15235392
[TBL] [Abstract][Full Text] [Related]
36. Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease.
Brewin J; Mancao C; Straathof K; Karlsson H; Samarasinghe S; Amrolia PJ; Pule M
Blood; 2009 Nov; 114(23):4792-803. PubMed ID: 19770360
[TBL] [Abstract][Full Text] [Related]
37. Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells.
Haque T; Taylor C; Wilkie GM; Murad P; Amlot PL; Beath S; McKiernan PJ; Crawford DH
Transplantation; 2001 Oct; 72(8):1399-402. PubMed ID: 11685111
[TBL] [Abstract][Full Text] [Related]
38. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.
Burns DM; Crawford DH
Blood Rev; 2004 Sep; 18(3):193-209. PubMed ID: 15183903
[TBL] [Abstract][Full Text] [Related]
39. Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8(+) T-cell restoration.
Porcu P; Eisenbeis CF; Pelletier RP; Davies EA; Baiocchi RA; Roychowdhury S; Vourganti S; Nuovo GJ; Marsh WL; Ferketich AK; Henry ML; Ferguson RM; Caligiuri MA
Blood; 2002 Oct; 100(7):2341-8. PubMed ID: 12239141
[TBL] [Abstract][Full Text] [Related]
40. Post-transplantation lymphoproliferative disorder after haematopoietic stem cell transplantation.
Pegoraro F; Favre C
Ann Hematol; 2021 Apr; 100(4):865-878. PubMed ID: 33547921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
